Synonyms: BMS-790052 | BMS790052 | Daklinza®
daclatasvir is an approved drug (EMA (2014), FDA (2015))
Compound class:
Synthetic organic
Comment: Daclatasvir is an orally available anti-hepatitis C virus (HCV) drug, It is a direct-acting inhibitor of the non-structural protein 5A (NS5A) replication complex of HCV [1]. Blocking NS5A function inhibits viral RNA replication and virion assembly.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Daclatasvir is used to treat hepatitis C infection. It is often used in fixed-dose combination with sofosbuvir. EMA and FDA authorisations have been withdrawn or discontinued, but the drug is available in other jurisdictions and is still on the WHO essential medicines list of anti-HCV drugs. |
External links |
For extended ADME data see the following: Drugs.com European Medicines Agency (EMA) |